Onconetix, Inc. (ONCO) stock
ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.43−0.05 (-10.13%)
Close on Oct 19, 2026Market cap $965.06KP/E –Yield –
Onconetix gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Onconetix's gross profit for the twelve months ending Jun 30, 2026 was $519.23K, down 41.1% year over year. For fiscal 2025 it was $632.91K, down 40.0% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $632.91K | -40.0% |
| FY2024 | Dec 31, 2024 | $1.06M | – |
| FY2023 | Dec 31, 2023 | -$1.13M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.30K | -93.9% |
| Q1 FY2026 | Mar 31, 2026 | -$1.66K | -103.6% |
| Q4 FY2025 | Dec 31, 2025 | $247.68K | -62.5% |
| Q3 FY2025 | Sep 30, 2025 | $268.89K | +155.1% |
| Q2 FY2025 | Jun 30, 2025 | $70.50K | -30.0% |
| Q1 FY2025 | Mar 31, 2025 | $45.83K | -75.8% |
| Q4 FY2024 | Dec 31, 2024 | $659.97K | – |
| Q3 FY2024 | Sep 30, 2024 | $105.41K | – |
| Q2 FY2024 | Jun 30, 2024 | $100.72K | – |
| Q1 FY2024 | Mar 31, 2024 | $189.00K | – |
See a number that looks wrong?